Bavencio plus Inlyta improves median PFS in renal carcinoma study

This article was originally published here

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced

The post Bavencio plus Inlyta improves median PFS in renal carcinoma study appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply